TNFRSF17 and plasma cell myeloma: These data suggest that complete responses of multiple myeloma after CD19 CAR-T therapy may only be accomplished in conjunction with another effective antimyeloma treatment, or a dual-antigen targeting approach where CAR-T concomitantly recognize CD19 in combination with, e.g., B-cell maturation antigen (BCMA) or another myeloma antigen9.